EIDD-2801
EIDD-2801 is an orally bioavailable prodrug of the potent ribonucleoside analog EIDD-1931. EIDD-2801 displays broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. EIDD-2801 could be potentially useful for COVID-19 treatment.
Product Specifications
Shipping Conditions
Gel Pack
Storage Conditions
-20ºC
Shelf Life
36 months
More Discoveries
Explore Other Products
Browse additional items from our catalog
K0279808 1.0 µg DNA
C10orf107 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)
Sign In for Pricing
View Details abx321757-01 20 µL
Lipopolysaccharide-Induced Tumor Necrosis Factor-Alpha Factor (LITAF) Antibody
Sign In for Pricing
View Details abx321757-02 50 µL
Lipopolysaccharide-Induced Tumor Necrosis Factor-Alpha Factor (LITAF) Antibody
Sign In for Pricing
View Details abx321757-03 100 µL
Lipopolysaccharide-Induced Tumor Necrosis Factor-Alpha Factor (LITAF) Antibody
Sign In for Pricing
View Details 
abx321757-04 200 µL
Lipopolysaccharide-Induced Tumor Necrosis Factor-Alpha Factor (LITAF) Antibody
Sign In for Pricing
View Details abx321757-05 1 mL
Lipopolysaccharide-Induced Tumor Necrosis Factor-Alpha Factor (LITAF) Antibody
Sign In for Pricing
View Details